Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Ноя. 14, 2024
Abstract
In
the
last
decade,
messenger
ribonucleic
acid
(mRNA)-based
drugs
have
gained
great
interest
in
both
immunotherapy
and
non-immunogenic
applications.
This
surge
can
be
largely
attributed
to
demonstration
of
distinct
advantages
offered
by
various
mRNA
molecules,
alongside
rapid
advancements
nucleic
delivery
systems.
It
is
noteworthy
that
immunogenicity
presents
a
double-edged
sword.
context
immunotherapy,
extra
supplementation
adjuvant
generally
required
for
induction
robust
immune
responses.
Conversely,
non-immunotherapeutic
scenarios,
activation
unwanted
considering
host
tolerability
high
expression
demand
mRNA-encoded
functional
proteins.
Herein,
mainly
focused
on
linear
non-replicating
mRNA,
we
overview
preclinical
clinical
progress
prospects
medicines
encompassing
vaccines
other
therapeutics.
We
also
highlight
importance
focusing
host-specific
variations,
including
age,
gender,
pathological
condition,
concurrent
medication
individual
patient,
maximized
efficacy
safety
upon
administration.
Furthermore,
deliberate
potential
challenges
may
encounter
realm
disease
treatment,
current
endeavors
improvement,
as
well
application
future
advancements.
Overall,
this
review
aims
present
comprehensive
understanding
mRNA-based
therapies
while
illuminating
prospective
development
drugs.
Язык: Английский
Developing mRNA Nanomedicines with Advanced Targeting Functions
Nano-Micro Letters,
Год журнала:
2025,
Номер
17(1)
Опубликована: Фев. 21, 2025
The
emerging
messenger
RNA
(mRNA)
nanomedicines
have
sprung
up
for
disease
treatment.
Developing
targeted
mRNA
has
become
a
thrilling
research
hotspot
in
recent
years,
as
they
can
be
precisely
delivered
to
specific
organs
or
tissues
enhance
efficiency
and
avoid
side
effects.
Herein,
we
give
comprehensive
review
on
the
latest
progress
of
with
targeting
functions.
its
carriers
are
first
described
detail.
Then,
mechanisms
passive
targeting,
endogenous
active
outlined,
focus
various
biological
barriers
that
may
encounter
during
vivo
delivery.
Next,
emphasis
is
placed
summarizing
mRNA-based
organ-targeting
strategies.
Lastly,
advantages
challenges
clinical
translation
mentioned.
This
expected
inspire
researchers
this
field
drive
further
development
technology.
Язык: Английский